S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?

Intra-Cellular Therapies (ITCI) Stock Forecast, Price & News

$59.38
-0.05 (-0.08%)
(As of 05/31/2023 ET)
Compare
Today's Range
$59.31
$61.00
50-Day Range
$45.89
$66.44
52-Week Range
$42.01
$66.56
Volume
490,998 shs
Average Volume
791,975 shs
Market Capitalization
$5.70 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$74.45

Intra-Cellular Therapies MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
25.4% Upside
$74.45 Price Target
Short Interest
Bearish
3.71% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.23
Upright™ Environmental Score
News Sentiment
0.09mentions of Intra-Cellular Therapies in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$6.19 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.32) to ($1.12) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.53 out of 5 stars

Medical Sector

141st out of 1,006 stocks

Pharmaceutical Preparations Industry

52nd out of 492 stocks


ITCI stock logo

About Intra-Cellular Therapies (NASDAQ:ITCI) Stock

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm's lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY.

Receive ITCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

ITCI Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
We Called (ARWR) In Advance, Which Stocks Are Next?
Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.
See More Headlines
Receive ITCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

ITCI Company Calendar

Last Earnings
5/04/2023
Today
6/01/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ITCI
Employees
512
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$74.45
High Stock Price Forecast
$98.00
Low Stock Price Forecast
$49.00
Forecasted Upside/Downside
+25.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Net Income
$-256,260,000.00
Pretax Margin
-73.46%

Debt

Sales & Book Value

Annual Sales
$250.31 million
Book Value
$6.54 per share

Miscellaneous

Free Float
92,377,000
Market Cap
$5.70 billion
Optionable
Optionable
Beta
1.15

Key Executives

  • Sharon MatesSharon Mates
    Chairman, President & Chief Executive Officer
  • Lawrence J. Hineline
    Chief Financial Officer, Treasurer & SVP-Finance
  • Robert E. Davis
    Chief Scientific Officer & Senior Vice President
  • Suresh DurgamSuresh Durgam
    Chief Medical Officer & Senior Vice President
  • Karen Patruno Sheehy
    Chief Compliance Officer & Senior Vice President













ITCI Stock - Frequently Asked Questions

Should I buy or sell Intra-Cellular Therapies stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ITCI shares.
View ITCI analyst ratings
or view top-rated stocks.

What is Intra-Cellular Therapies' stock price forecast for 2023?

10 brokers have issued 1-year price targets for Intra-Cellular Therapies' shares. Their ITCI share price forecasts range from $49.00 to $98.00. On average, they expect the company's stock price to reach $74.45 in the next twelve months. This suggests a possible upside of 25.4% from the stock's current price.
View analysts price targets for ITCI
or view top-rated stocks among Wall Street analysts.

How have ITCI shares performed in 2023?

Intra-Cellular Therapies' stock was trading at $52.92 at the beginning of 2023. Since then, ITCI stock has increased by 12.2% and is now trading at $59.38.
View the best growth stocks for 2023 here
.

Are investors shorting Intra-Cellular Therapies?

Intra-Cellular Therapies saw a increase in short interest in May. As of May 15th, there was short interest totaling 3,560,000 shares, an increase of 21.9% from the April 30th total of 2,920,000 shares. Based on an average trading volume of 893,600 shares, the short-interest ratio is presently 4.0 days.
View Intra-Cellular Therapies' Short Interest
.

When is Intra-Cellular Therapies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our ITCI earnings forecast
.

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) posted its quarterly earnings data on Thursday, May, 4th. The biopharmaceutical company reported ($0.46) EPS for the quarter, beating analysts' consensus estimates of ($0.63) by $0.17. The biopharmaceutical company earned $95.31 million during the quarter, compared to analysts' expectations of $92.14 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 33.92% and a negative net margin of 73.46%.

What other stocks do shareholders of Intra-Cellular Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).

What is Intra-Cellular Therapies' stock symbol?

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Who are Intra-Cellular Therapies' major shareholders?

Intra-Cellular Therapies' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (12.45%), BlackRock Inc. (7.58%), Wellington Management Group LLP (5.24%), Wasatch Advisors LP (4.67%), State Street Corp (2.11%) and JPMorgan Chase & Co. (1.91%). Insiders that own company stock include Christopher D Alafi, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Lawrence J Hineline, Mark Neumann, Michael Halstead, Nostrand Robert L Van, Rory B Riggs, Sharon Mates and Suresh K Durgam.
View institutional ownership trends
.

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intra-Cellular Therapies' stock price today?

One share of ITCI stock can currently be purchased for approximately $59.38.

How much money does Intra-Cellular Therapies make?

Intra-Cellular Therapies (NASDAQ:ITCI) has a market capitalization of $5.70 billion and generates $250.31 million in revenue each year. The biopharmaceutical company earns $-256,260,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis.

How many employees does Intra-Cellular Therapies have?

The company employs 512 workers across the globe.

How can I contact Intra-Cellular Therapies?

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The official website for the company is www.intracellulartherapies.com. The biopharmaceutical company can be reached via phone at (464) 440-9333, via email at ir@intracellulartherapies.com, or via fax at 646-440-9334.

This page (NASDAQ:ITCI) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -